High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

Completed · Phase 3 · Has a placebo group

Conditions studied: Atherosclerosis, Cardiovascular Disease

In brief

The purpose of this study is to investigate the added benefits of increased high-density lipoprotein (HDL) cholesterol serum levels over and above those achieved by lipid lowering therapy guided by current guidelines, in older individuals with cardiovascular disease.

Key facts

Study ID

NCT00127218

Run by

Johns Hopkins University

People needed

145

Starts

2003-09-01

Expected to finish

2008-12-01

Last updated by the study team

2017-11-06

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 65 or older
• Documented clinical cardiovascular or cerebrovascular disease due to atherosclerosis
• Candidate for lipid lowering therapy; no contraindication to fluvastatin, niacin or aspirin therapy
• Low-density lipoprotein (LDL) cholesterol below 150 mg/dl if untreated or below 125 mg/dl on statin monotherapy
• Willing to discontinue present therapy if private physician agrees with enrollment
• Eligible to undergo trans-esophageal magnetic resonance imaging (MRI); no contraindications to Gadolinium-DTPA, the contrast agent used
• Willing to sign Informed Consent

You may not qualify if…

• Ineligibility for MRI procedure due to pacemaker, metal implants, or other ferromagnetic devices
• Claustrophobia
• Previously documented esophageal disease which would preclude trans-esophageal MRI
• LDL-C greater than 150 mg/dl off lipid lowering therapy or daily statin therapy requiring doses greater than 20 mg of atorvastatin, 20 mg of simvastatin, 80 mg of lovastatin, 80 mg of pravastatin, 80 mg of extended release fluvastatin, or 20 mg of rosuvastatin
• Contraindication or allergy to statins or aspirin
• Current use of or known intolerance or allergy to Niaspan (a long-acting niacin)
• Allergy or intolerance to Gadolinium-DTPA (MRI contrast agent)
• Liver or kidney failure defined clinically and by laboratory data
• Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial

Where it is running

• Johns Hopkins Unversity School of Medicine — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.